Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy
Recently, our group reviewed the strategies of using extracellular vesicles to deliver macromolecular drugs in cancer immunotherapy. The content was published online in Journal of Controlled Release under the title of “Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy”.
Great attention has been paid to the impressive role the macromolecules played in cancer immunotherapy, however, the applications were largely limited by their poor circulation stability, low cellular uptake efficiency, and off-target effects. As an important messenger of intercellular communication, extracellular vesicles (EVs) exhibit unique advantages in macromolecule delivery compared to traditional synthetic carriers, offering new possibilities for modern drug delivery. These naturally derived carriers can achieve stable, efficient, and selective delivery of macromolecules and improve the efficacy and potentiality of macromolecular drugs in cancer immunotherapy.
This review provides a brief overview of the unique features of EVs related to macromolecule delivery, the strategies and recent advances of using EVs as macromolecule delivery carriers in cancer immunotherapy.
Hongyi Chen, the PhD fellow of 2019 from the School of Pharmacy, Fudan University, is the first author, while Professor Chen Jiang is the corresponding author. The work was supported by grants from the National Natural Science Foundation of China, Key Projects of Shanghai Science Foundation, Shanghai Municipal Science and Technology Major Project, and ZJLab.
For more information: https://doi.org/10.1016/j.jconrel.2022.06.014
